Fierce Pharma

OCTOBER 16, 2023

As the coronavirus outbreak has shifted to the endemic phase, drugmakers have warned of a drop in demand for COVID-19 products, with the impact coming into focus during the fall vaccination season. | Pfizer has slashed its 2023 revenue projection by $9 billion because of declining demand for COVID products. The company now expects sales to reach between $58 billion and $61 billion, down from a prior range of $67 billion to $70 billion.

Sales 361

Sales 361

Pharmaceutical Technology

OCTOBER 18, 2023

The FDA approved Hyloris’s non-opioid painkiller as the agency increases efforts to mitigate an opioid crisis.

FDA 145

FDA 145

PharmaVoice

OCTOBER 19, 2023

The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

Patients 138

Patients 138

MedCity News

OCTOBER 15, 2023

The FDA’s digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.

FDA 131

FDA Patients Biopharma 131

Advertiser: ZoomInfo

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

Sales

Fierce Pharma

OCTOBER 16, 2023

Up until this point, immune checkpoint inhibitors have been allowed to treat early-stage non-small cell lung cancer (NSCLC) either before or after surgery. | Thanks to a new FDA approval for Merck's Keytruda, a continuous immunotherapy regimen around surgery is now available for patients with early-stage non-small cell lung cancer. The drug's label already includes an overall survival win from a key trial.

FDA 331

FDA Patients 331

David Bagga

OCTOBER 18, 2023

The final step of the interview process is usually meeting with a regional sales director or VP of sales, companies will determine who you need to meet with during a final interview. Medical Device Sales Career Home Blog Win Your Medical Device Sales Job… Win Your Medical Device Sales Job The Final Interview The Final […] The post Win Your Medical Device Sales interview appeared first on.

Sales 130

Sales Medical Regional sales Medical sales reps 130

MedCity News

OCTOBER 16, 2023

At HLTH, Mayo Clinic Platform President John Halamka gave a window into how his health system is mitigating generative AI risks. Some of the measures Mayo is taking include running analyses on how well algorithms perform across various subgroups and training models only on internal de-identified data.

Training 130

Training Healthcare Healthcare 130

Fierce Pharma

OCTOBER 18, 2023

Editor's Note: Please check back on Oct. 22 when the full data of EV-302 are presented at ESMO 2023. | The results are in for a phase 3 bladder cancer trial assessing the combination of Seagen and Astellas' Padcev, plus Merck's Keytruda, versus standard of care chemotherapy. The figures indicate that the combo can be transformative in the indication.

294

294

PharmaVoice

OCTOBER 16, 2023

Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

122

122

European Pharmaceutical Review

OCTOBER 18, 2023

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor. Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease ( CKD ) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

Food and Drug Administration 119

Food and Drug Administration FDA Food Patients 119

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

MedCity News

OCTOBER 18, 2023

Investing in Friction-reducing tactics such as community building and providing benefits, training, and personalized support to employees will yield compounding long-term benefits while reducing churn rate.

Doctors 123

Doctors Training Healthcare Healthcare 123

Fierce Pharma

OCTOBER 17, 2023

Editor's note: This is an evolving story. Please check back on Oct. 23 when the full data of MARIPOSA are presented at ESMO 2023. | A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the EGFR king.

288

288

PharmaVoice

OCTOBER 17, 2023

Phenylephrine’s future is up in the air with an FDA committee saying it’s not effective and a class action lawsuit alleging false advertising. What comes next could have big repercussions.

FDA 119

FDA Medicine 119

PharmaTimes

OCTOBER 17, 2023

The two projects will investigate the potential causes of Parkinson’s disease - News - PharmaTimes

117

117

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

MedCity News

OCTOBER 15, 2023

This year’s HLTH conference brought a bevy of news announcements — from partnerships to new product features to acquisitions and more. In this list, MedCity News compiled short summaries for 11 of the conference’s most notable announcements.

122

122

Fierce Pharma

OCTOBER 20, 2023

Eli Lilly is on a roll with its RET inhibitor Retevmo, with new trial results showing the drug can offer dramatic benefits in the treatment of certain lung and thyroid cancers. | Eli Lilly is on a roll with its RET inhibitor Retevmo, with new trial results showing the drug can offer dramatic benefits in the treatment of certain lung and thyroid cancers.

Competition 266

Competition 266

European Pharmaceutical Review

OCTOBER 20, 2023

A paper by Tim Sandle, Head of Microbiology, Risk Management and Sterility Assurance at Bio Products Laboratory Ltd has underlined the importance of proper cleanroom disinfection practices by elucidating on the robust survival mechanism of the bacterium Micrococcus luteus (M. luteus). As “one of the most abundant organisms on the outer layer of human skin” M. luteus is a common contaminant recovered from cleanrooms, according to Sandle.

Pharmaceutical 116

Pharmaceutical Management 116

PharmaTimes

OCTOBER 20, 2023

Global innovators can apply to PACE to receive up to £1m per project - News - PharmaTimes

116

116

Advertisement

MedCity News

OCTOBER 16, 2023

Microsoft rolled out several AI tools at the HLTH conference last week to enable providers to harness the power of data to be more efficient in their care delivery efforts. The overarching goal is to reduce costs, burnout and improve outcomes. Called Microsoft Fabric, which was rolled out broadly in May, the announcement on October 10 marks the availability of Fabric’s capabilities specifically for the healthcare vertical – to clinicians, administrators but perhaps, most importantly,

Healthcare 120

Healthcare Healthcare Patients Doctors 120

Fierce Pharma

OCTOBER 18, 2023

Pfizer will cough up $2 million to settle allegations from the U.S. Department of Labor that it underpaid certain women who were employed at the company’s New York City headquarters. | The accusations centered on the company's compensation of 86 female employees in 2015 and 2016. Under the settlement with the Department of Labor, the company must also set aside $500,000 for potential future salary adjustments.

262

262

pharmaphorum

OCTOBER 18, 2023

Seagen wins future royalties in Enhertu patent dispute Phil.

114

114

Pharmaceutical Technology

OCTOBER 18, 2023

Lisata has received orphan drug designation from the EMA's Committee for Orphan Medicinal Products for LSTA1 to treat pancreatic cancer.

Medicine 114

Medicine 114

Advertiser: ZoomInfo

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

Sales Strategy

MedCity News

OCTOBER 18, 2023

FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.

FDA 120

FDA Marketing Biopharma Pharma 120

Fierce Pharma

OCTOBER 16, 2023

Bristol Myers Squibb’s star Opdivo now can lay claim to an earlier melanoma stage with a new approval that “reinforces the company’s legacy” in treating the cancer type, it said. | Bristol Myers Squibb's Opdivo can now treat completely resected stage 2B or 2C melanoma, adding to its existing approvals in stages 3 and 4 tumors and setting up an expanded market battle with Merck & Co.'s star Keytruda.

Marketing 261

Marketing 261

Impetus Digital

OCTOBER 20, 2023

Register for one of Impetus’ upcoming webinars between November 20-24: Digital Learning Programs with a Twist About the webinar Last year, we hosted a series of webinars on virtual learning programs. By popular demand, we are bringing them back in November, featuring all the new best practices, tips, and tricks that we’ve picked up in the last 12 months.

Education 113

Education Professional Services Training Healthcare Provider 113

PharmaTimes

OCTOBER 20, 2023

The new technology was safely trialled on 20 healthy volunteers for the first time ever - News - PharmaTimes

113

113

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

MedCity News

OCTOBER 19, 2023

With its new handheld ultrasound device, Exo is seeking to take point-of-care ultrasound beyond just the emergency medicine field — into areas like urgent care, primary care and the home. Kurt Hammond, Exo’s chief commercial officer, said that the device sets itself apart from other handheld ultrasound devices, such as those sold by GE, Philips and Butterfly Network, because its AI does a better job of making the ultrasound process quick and easy for providers.

Networking 114

Networking Medicine Medical Healthcare 114

Fierce Pharma

OCTOBER 19, 2023

Months after ditching an auto-injected version of Opdivo (nivolumab), Bristol Myers Squibb has found success with a more traditional way to administer its oncology blockbuster—with a syringe and vi | Months after ditching an auto-injected version of Opdivo, Bristol Myers Squibb has found success with a more traditional way to administer its oncology blockbuster—with a syringe and vial.

250

250

pharmaphorum

OCTOBER 19, 2023

Pfizer sets Paxlovid price at nearly $1,400 per course Phil.

112

112

PharmaTimes

OCTOBER 18, 2023

Around 700 people in the UK could benefit from the new treatment - News - PharmaTimes

111

111

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety